Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMET PRO
2024-516383-28-01Phase 3Authorised
- Sponsor
- Azienda USL di Bologna
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cabergoline in prolactinoma and hyperprolactinemia (2 arms), sponsored by Azienda USL di Bologna. Primary endpoint: Biochemical remission at 6 and 12 months. Planned start Sep 2024; status: authorised.
02
Drugs
cabergoline
03
Conditions
prolactinomahyperprolactinemia
Beyond the preview
Go deeper on 2024-516383-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516383-28-01.